MetaCap

Galectin Therapeutics Inc. (GALT)

NASDAQ: GALTHealth CareBiotechnology: Pharmaceutical PreparationsUSD

2.69-0.12 (-4.27%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

GALT stock chart

Technical analysis

Key statistics

All statistics
Market cap
$271.35M
EPS (TTM)
-$0.32
52-week range
2.03 – 7.13
Day range
2.67 – 2.93
Volume / Avg
257.65K / 252.31K
Beta
—

52-week range

$2.03$7.13

GALT stock today

Shares of Galectin Therapeutics (GALT) finished lower on Nov 20 at $2.69, a drop of 4.27% or $0.12 per share, versus the S&P 500's 3.70% decline. At this level, GALT sits near the bottom of its 52-week range of $2.03 to $7.13: 62.3% below the high, set on Dec 17, 2025 and 32.5% above the low. GALT is down 35.3% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 49.7%.

Galectin Therapeutics has posted a net loss over the last twelve months (EPS of -$0.32), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Galectin Therapeutics

Company profile

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in drug development to create new therapies for fibrotic disease and cancer. The company's lead product candidate is belapectin (GR-MD-02), a galectin-3 inhibitor, which is in a Phase 2 clinical study in MASH patients with advanced fibrosis and a second Phase 2b clinical trial in MASH patients with compensated cirrhosis and portal hypertension. It has a joint venture co-owned by SBH Sciences, Inc.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Mr. Joel Lewis CPA
Headquarters
Norcross, GA
Employees
9

Financial highlights

Full financials

Galectin Therapeutics reported a net loss of $30.8 million, compared with a loss of $47.0 million a year earlier. Diluted earnings per share came in at -$0.48.

Galectin Therapeutics annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue—————
Growth—————
Net income$-30.84M$-47.05M$-41.07M$-38.78M$-30.53M
EPS (diluted)$-0.48$-0.76$-0.74$-0.65$-0.52

Analyst forecast

Forecast

Consensus (1 analysts)

strong_buy

Avg. price target

$11.00+308.92%

  • Strong buy 0
  • Buy 1
  • Hold 0
  • Sell 0
  • Strong sell 0

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 16, 2026
EPS actual vs est.
$-0.04 vs $-0.05
Surprise
+20.00%

GALT news

All GALT news

Galectin Therapeutics peers

Health Care sector
GALT peer companies
CompanyPrice% ChgMarket capCompare
VCREVicore Pharma Holding AB ADR9.41-5.09%$264.89Mvs GALT
RLMDRelmada Therapeutics Inc.2.62-15.76%$279.54Mvs GALT
FULCFulcrum Therapeutics Inc.3.69-0.54%$281.85Mvs GALT
GLSIGreenwich LifeSciences Inc.19.25-2.73%$282.56Mvs GALT
EBSEmergent BioSolutions Inc.5.05-1.94%$259.65Mvs GALT
ALTAltimmune Inc.1.33-5.67%$258.80Mvs GALT
PRLDPrelude Therapeutics Incorporated3.23-0.77%$258.63Mvs GALT
BNTCBenitec Biopharma Inc.7.92-2.76%$285.88Mvs GALT

Indexes, lists and sector

Galectin Therapeutics stock FAQ

What is Galectin Therapeutics's stock price today?

GALT last traded at $2.69 as of Nov 20, 4:00 PM EST, down 4.27% on the day. Prices are delayed at least 15 minutes.

Does Galectin Therapeutics pay a dividend?

No. Galectin Therapeutics does not currently pay a regular cash dividend.

Who is Galectin Therapeutics's CEO?

Mr. Joel Lewis CPA is the chief executive officer of Galectin Therapeutics Inc., which has about 9 employees.

Has GALT ever split its stock?

Yes. The most recent GALT stock split was a 1-for-6 split on Mar 23, 2012.

What is the GALT 52-week high?

The 52-week high for GALT is $7.13 and the 52-week low is $2.03. The stock is currently 62.3% below its high.

Compare GALT